[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event

Rhea-AI Filing Summary

Enanta Pharmaceuticals, Inc. (ENTA) filed a current report to announce that it released a press release with its financial results for the fiscal quarter and year ended September 30, 2025. The press release, dated November 17, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed numbers and commentary are contained in that exhibit rather than in the body of this report. This filing is a standard earnings disclosure under Item 2.02 of the Exchange Act.

Insights

Equity analyst – biotech earnings

Routine 8-K furnishing Enanta’s FY 2025 results press release, neutral impact.

Enanta Pharmaceuticals is using this 8-K to formally furnish its financial results for the fiscal quarter and year ended September 30, 2025 via a press release attached as Exhibit 99.1. This is a common practice for U.S.-listed companies and signals that the substantive earnings discussion is contained in the accompanying exhibit.

The use of Item 2.02 and incorporation by reference indicates this is primarily an informational disclosure rather than announcing a new transaction or strategic shift. Without the underlying numbers, margin trends or pipeline updates cannot be evaluated from this excerpt alone, so it does not, by itself, change an investment thesis.

Investors typically focus on the detailed revenue, R&D spending, cash position, and pipeline commentary in the press release and subsequent filings covering the period ended September 30, 2025. Those figures and narratives, rather than this administrative 8-K wrapper, would drive any reassessment of Enanta’s outlook.

0001177648false00011776482025-11-172025-11-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35839	04-3205099
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4 Kingsbury Avenue
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		ENTA		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 17, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release of Enanta Pharmaceuticals, Inc. dated November 17, 2025, reporting Enanta's financial results for the fiscal quarter and year ended September 30, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			ENANTA PHARMACEUTICALS, INC.
Date:	November 17, 2025	By:	/s/ Jay R. Luly, Ph.D.
			Jay R. Luly, Ph.D. President and Chief Executive Officer